From 13 till 17 September 2024: HIGHLIGHTS FROM ESMO
Your direct line with Barcelona
The European Society of Medical Oncology (ESMO) 2024 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Barcelona, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
Presidential highlights
Prof Dr Silke Gillessen, a medical oncologist at the EOC – Ospedale Regionale Bellinzona e Valli in Bellinzona, Switzerland, had the distinction of presenting the Late Breaking Abstract 1 as
Daily highlights in GU
Dr Tom Van den Mooter and Dr Michiel Strijbos from ZAS Hospital in Antwerp shared key takeaways from ESMO 2024 regarding prostate cancer. They highlighted several trials, noting that some
Professor Emmanuel Seront, medical oncologist at Cliniques Universitaires Saint-Luc in Belgium, provides a selection of highlights in urothelial and renal cancer from the mini oral session at ESMO.
There is
Dr Jérémy Blanc, medical oncologist in training at the Jules Bordet institute in Brussels discusses the key results of four clinical trials that were presented during the second proffered paper
In this video, Dr Annelies Verbiest, medical oncologist at the University hospital Antwerp shares the results of 5 clinical trials that were presented in a first of two proffered paper
In-depth stories about GU
In this video, Prof Dr Karim Fizazi, medical oncologist at the Institut Gustave Roussy in Villejuif, France, shares the highlights of an educational session at ESMO 2024 dedicated to emerging
During ESMO 2024, Prof Dr Fred Saad (Centre Hospitalier de l’Université de Montréal, Montréal, Canada) presented the primary results of this trial.
In this video, Prof Dr Christof Vulsteke from the Integrated Cancer Center in Ghent and Dr Tom Van den Mooter, medical oncologist in the Ziekenhuis aan de Stroom (ZAS) in
Prof Christof Vulsteke, medical oncologist at the Integrated Cancer Center Gent, discussed the outcomes of the SUNRISE-1 trial with Prof Charles van Praet, urologist at the University of Gent and
Prof Brian Rini, a medical oncologist at Vanderbilt Ingram Cancer Center, Nashville, TN presented an update on the LightSpark005 trial, which compared belzutifan to everolimus in patients with previously treated
Prof Alexandra Drakaki, Medical Director of GU Oncology at UCLA, presented findings from the VOLGA trial, a phase 3 study focused on MIBC patients who are ineligible for cisplatin-based chemotherapy.
GU poster selection
In this video, Dr Renée Bultijnck takes us through the key take-aways from this analysis.
To address this issue, Danielle Delombaerde, pharmacist at the Integrated Cancer Center in the General Hospital AZ Maria Middelares in Ghent and colleagues set up a study to describe the
During ESMO 2024, Dr Annelies Verbiest, medical oncologist at the University Hospital Antwerp, presented the results of a real-world analysis looking into the treatment patterns of immune checkpoint inhibitors (ICIs)
Made possible with the financial support of our partners.
All videos are developed independently and are non-promotional.
